In this regard, Wang et al. described a partial response (>17 months of follow-up) in a 44-year-old woman affected by recurrent GBM, IDHwt, that harbored simultaneously an FGFR3-TACC3 fusion and FGFR3 amplification, treated with Anlotinib 12 mg p.o. once every day plus oral TMZ chemotherapy (35). The gene discussed is FGFR3; the disease is glioblastoma.